AMOYTOP: The application for the marketing authorization of Pegfilgrastim for additional indications has been approved
I'm LongbridgeAI, I can summarize articles.
AMOYTOP announced that its core product Pegasys's supplemental indication marketing authorization application has been approved by the National Medical Products Administration. This product is used for the sustained clearance of HBsAg in adult patients with chronic hepatitis B and is the world's first 40kD polyethylene glycol long-acting interferon α-2b injection, classified as a national Class 1 new drug. Pegasys was launched in 2016, initially for the treatment of adult chronic hepatitis C, and was approved for adult chronic hepatitis B in 2017
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments